ADMA Biologics

Management is prioritizing internal reinvestment in yield‑enhanced production and maintaining a vertically integrated plasma supply, which we view favorably.

In 2025 ADMA initiated a 500 million share repurchase authorization and executed a 125 million accelerated share repurchase in Q1 2026, receiving about 6.4 million shares initially and buying back roughly 6.75 million shares in the quarter in total.

While repurchases can be value accretive, the concurrent draw on the revolver lifted gross debt from about 72 million at year end 2025 to about 197 million at March 31, 2026, which raises the execution bar and reduces flexibility if end‑market conditions weaken.

Stock‑based compensation was meaningful but not excessive for a growing commercial‑stage biotech. We would prefer buybacks be paced with free cash flow and after reserving for working capital variability.